Jorge Mercado, MD
Pulmonary Disease · Erie, PANPI 1447411970
Payments from drug & device makers
Across 268 payments — averaging $160.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$24K
- Intuitive Surgical$5K
- Medical Device Business Services, Inc.$4K
- Noah Medical Corporation$3K
- Advanced Respiratory, Inc$2K
- Galvanize Therapeutics, Inc$847
- plus $5K from 24 others
What the payments were for
- Consulting fees$7,82329%
- Speaking & faculty fees$1,6406%
- Travel & lodging$2,91511%
- Food & beverage$9,73336%
- Education$4,57917%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 46 | $23,705 |
| Intuitive Surgical | 11 | $4,774 |
| Medical Device Business Services, Inc. | 12 | $3,739 |
| Noah Medical Corporation | 15 | $2,807 |
| Advanced Respiratory, Inc | 8 | $1,796 |
| Galvanize Therapeutics, Inc | 14 | $847 |
| Sanofi | 28 | $742 |
| Genentech USA, Inc. | 13 | $511 |
| Pentax Of America, Inc. | 1 | $500 |
| Boehringer Ingelheim | 23 | $457 |
| GSK | 22 | $449 |
| AstraZeneca | 16 | $371 |
| Regeneron Healthcare Solutions, Inc. | 7 | $331 |
| Body Vision Medical Inc. | 2 | $315 |
| Actelion Pharmaceuticals US, Inc. | 3 | $244 |
| Olympus America Inc. | 3 | $168 |
| Jazz Pharmaceuticals Inc. | 1 | $150 |
| Amgen | 7 | $142 |
| Ambu Inc. | 1 | $125 |
| Verona Pharma, Inc. | 4 | $120 |
| Boston Scientific | 5 | $115 |
| Philips North America LLC | 6 | $115 |
| Baxter Healthcare | 6 | $110 |
| Mylan Specialty L.p. | 4 | $94 |
| Insmed, Inc. | 2 | $91 |
| Sanofi-aventis U.S. LLC | 1 | $67 |
| Electromed, Inc. | 3 | $62 |
| Pfizer | 2 | $31 |
| AbbVie | 1 | $23 |
| Grifols USA, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Monarch Platform$8,858
- Da Vinci Surgical System$4,705
- The Vest System 205 Acute Care$1,640
- Volara System$1,640
- The Monarch Airway Clearance System$1,640
- The MetaNeb System$1,640
- SynclaraCough System$1,640
- MONARCH$1,308
- GALAXY$352
- ALIYA SYSTEM$321
- LungVision$220
- XYWAV$150
- Esbriet$140
- FASENRA$126
- BREZTRI$126
- FARXIGA$126
How this compares
$43,018 in reported general payments places this provider in the 85th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 702 | $542,137 |
| TezspireTezepelumab-Ekko | 109 | $497,598 |
| ArikayceAmikacin Liposomal/Neb.Accessr | 25 | $398,033 |
| Dupixent PenDupilumab | 61 | $224,725 |
| OfevNintedanib Esylate | 12 | $166,688 |
| Breo ElliptaFluticasone/Vilanterol | 325 | $161,072 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 71 | $47,418 |
| Spiriva RespimatTiotropium Bromide | 67 | $44,411 |
| Arnuity ElliptaFluticasone Furoate | 155 | $44,367 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 70 | $40,665 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 51 | $26,751 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 679 | $22,086 |
| Incruse ElliptaUmeclidinium Bromide | 43 | $17,752 |
| Advair HfaFluticasone Propion/Salmeterol | 36 | $12,824 |
| EliquisApixaban | 19 | $11,568 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Anoro Ellipta, Incruse Ellipta | $449 | $805,9931,295 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $371 | $554,557224 claims |
| Insmed, Inc.Arikayce | $91 | $398,03325 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $457 | $237,850130 claims |
| PfizerEliquis | $31 | $11,56819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 703 pulmonary disease providers in Pennsylvania.
Other pulmonary disease in Erie
- Stephen KovacsErie$520K
- Gerard CrinerPhiladelphia$18.2M
- Sandeep Bansaldu Bois$8.9M
- David WheelerPhiladelphia$7.7M
- Steven AlbeldaPhiladelphia$5.5M
- Paul SimonelliDanville$2.1M
- Kevin GibsonPittsburgh$1.3M
- Frank SciurbaPittsburgh$1.2M
- Joseph PilewskiPittsburgh$1M
- Steven DuncanPittsburgh$995K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.